Navigation Links
ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
Date:5/15/2008

TUCSON, Ariz., May 15 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX), a biopharmaceutical company developing and commercializing therapies for vascular disorders, today reported financial results for the first quarter ended March 31, 2008 and discussed recent corporate highlights.

Corporate Highlights:

-- Entered into agreement with Abbott Laboratories satisfying remaining

debt obligation under non-recourse promissory note issued in connection

with the Company's urokinase acquisition.

-- Signed letter of intent to sell urokinase inventory and related assets

to Microbix Biosystems for $17 million in cash: $12 million at closing

and $5 million upon achievement of an inventory stability milestone.

-- Identified strategic funding to continue advancement of its core

SonoLysis program upon closing of urokinase divestiture with Microbix

Biosystems.

Bradford A. Zakes, President and CEO of ImaRx stated, "Through the satisfaction of our debt obligation with Abbott under favorable terms and the pending divestiture of our urokinase asset to Microbix, we will have successfully gained access to operating capital that is non-dilutive to our shareholders. Taken together, these events have provided us the strategic alternative to continue the advancement of our core SonoLysis technology within ImaRx."

Financial Results

Revenue for the first quarter ended March 31, 2008 rose to $1.9 million from $1.2 million for the first quarter ended March 31, 2007. Increased sales of urokinase, which ImaRx began commercializing in October 2006, drove the revenue increase for the quarter.

Net loss for the first quarter of 2008 was $2.5 m
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ImaRx Postpones Release of First Quarter 2008 Financial Results
2. ImaRx Schedules Release of First Quarter 2008 Financial Results
3. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
4. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
5. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
6. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
7. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
8. ImaRx to Report Corporate Updates and 4Q07 Financial Results
9. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
10. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Nile Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market ... in Americas with analysis and forecast of revenue. ... Inorganic Refrigerants Market report, to get an idea ... a glimpse of the segmentation in the Americas ... tables and figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html ...
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... UAE (PRWEB) October 22, 2014 Grace ... science and healthcare projects, announces the addition of ... DCH to its advisory team. Dr. Siddiqui will provide ... , A graduate of University College Medical ... subsequently degreed in medicine in 2001. With further certification ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... NOVATO, Calif., Sept. 2 BioMarin,Pharmaceutical Inc. (Nasdaq: ... of BioMarin, will present a company,update at the Morgan ... September 9, 2008 at 1:35 p.m. ET., Interested ... conference,call via the investor section of the BioMarin website, ...
... Signalife, Inc. (Amex:,SGN) announced earlier today that ... of the market, regarding the law firm of ... Signalife, Inc. is a life sciences company focused ... continuous biomedical signal,monitoring. Signalife uses its patented signal ...
... SAN DIEGO, Sept. 2 Halozyme Therapeutics,Inc. ... developing and,commercializing products targeting the extracellular matrix, ... Vice President,Research, Michael J. LaBarre, PhD, Vice ... President, Legal., "Halozyme is committed to ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Global Healthcare Conference 2Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 3Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 4
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... The American Dietetic Association has released an updated ... if well-planned, are healthful and nutritious for adults, infants, ... chronic diseases including heart disease, cancer, obesity and diabetes. ... the Journal of the American Dietetic Association , ...
... have uncovered new evidence suggesting that damage to nerve ... body,s natural mechanism for repair of the nerve coating ... today, July 1, 2009, in the print edition of ... at the University of California, San Francisco and University ...
... The Netherlands: For the first time, researchers have been ... failure of IVF treatment in blood. Dr. Cathy Allen, from ... of the European Society of Human Reproduction and Embryology today ... IVF works for some patients but not for others. ...
Cached Biology News:ADA releases updated position paper on vegetarian diets 2MS study offers theory for why repair of brain's wiring fails 2MS study offers theory for why repair of brain's wiring fails 3Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3
This modular benchtop laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Options include a work bench, ionizaing bar, and air velocity gauge....
...
... Thermo Scientific ChromQuest Chromatography Data System ... digital data acquisition, chromatography data processing ... Accela High Speed LC. The companys ... to maximize the benefits of Thermo ...
...
Biology Products: